David Yu Zhang

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA.

IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Centrillion Technology Holdings Ltd. provides genomics solutions. Its products and services can isolate, manipulate, visualize and analyze intact kilobase and megabase fragments of DNA. The company was founded by Wei Zhou in 2009 and is headquartered in Palo Alto, CA.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

MegaRobo Technologies Co., Ltd. develops TV internal visual inspection equipment for LED TV assembly production processes. The equipment can be widely used in mobile phones, car displays, and large-size TV panel production lines. The company is based in Beijing, China. The equipment detects various defects such as missing screws, misplaced adhesive tape, loose terminals, and incorrect positioning of magnetic rings and wires. It provides automatic detection and alarm, and can upload production information to MES systems for easy traceability. The Chinese company was founded in 2016 by Yu Qing Huang, Zhi Xin Qiao, Yan Zhang. Yu Qing Huang has been the CEO since 2016.

CarrierGene Biotech Co., Ltd. engages in the identification of the causes of infertility for patients through genetic testing technology and data analysis algorithms. The company was founded in 2016 and is headquartered in Suzhou, China.

Torus Biosystems, Inc. engages in the provision of biotechnology services. It performs DNA testing for scientific and medical research purposes. The company was founded in 2019 and is headquartered in Brookline, MA.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

First Bight Ventures (First Bight) is a venture capital firm founded in 2021 by Veronica B Wu. The firm is headquartered in Houstan, Texas.